Anticancer properties of Monascus metabolites

Anti-Cancer Drugs

Volumn 25, Issue 7, 2014, Pages 735-744

  Yang, Tao ^a,c   Liu, Junwen ^a   Luo, Feijun ^a   Lin, Qinlu ^a   Rosol, Thomas J ^d   Deng, Xiyun ^a,b  

^a CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

cancer; lovastatin; Monascus metabolites; red mold rice

Indexed keywords

ANTINEOPLASTIC AGENT; FUNGAL EXTRACT; MEVINOLIN; NATURAL PRODUCT; POLYSACCHARIDE; STEROID; BIOLOGICAL PRODUCT; RADIOSENSITIZING AGENT;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER INCIDENCE; CANCER MORTALITY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; DRUG MECHANISM; DRUG SENSITIZATION; FERMENTED PRODUCT; HUMAN; METABOLITE; MONASCUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL MOTION; DRUG EFFECTS; FERMENTATION; METABOLISM; METASTASIS; NEOPLASM INVASIVENESS; NEOPLASMS; PATHOLOGY; RADIATION DOSE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BIOLOGICAL PRODUCTS; CELL MOVEMENT; FERMENTATION; HUMANS; MONASCUS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84903815139     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000102     Document Type: Review

References (78)

1. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000; 48: 5220-5225.
2. Lin YL, Wang TH, Lee MH, Su NW. Biologically active components and nutraceuticals in the Monascus-fermented rice: a review. Appl Microbiol Biotechnol 2008; 77:965-973.
3. Feng Y, Shao Y, Chen F. Monascus pigments. Appl Microbiol Biotechnol 2012; 96:1421-1440.
4. Patakova P. Monascus secondary metabolites: production and biological activity. J Ind Microbiol Biotechnol 2013; 40:169-181.
5. Hsu WH, Pan TM. Monascus purpureus-fermented products and oral cancer: a review. Appl Microbiol Biotechnol 2012; 93:1831- 1842.
6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Pr evention Study. JAMA 1998; 279:1615-1622. (Pubitemid 28248586)
7. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use a nd breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004; 100:2308-2316. (Pubitemid 38657877)
8. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192. (Pubitemid 40727085)
9. Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, et al. Thalidomide, dexamethasone and lovastati n with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol 2011; 90: 1161-1166.
10. Thibault A, Samid D, Tompk ins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2:483-2491.
11. Zheng Y, Xin Y, Shi X, Guo Y. Cytotoxicity of Monascus pigments and their derivatives to human cancer cells. J Agric Food Chem 2010; 58: 9523-9528.
12. Su NW, Lin YL, Lee MH, Ho CY. Ankaflavin f rom Monascus-fermented red rice exhibits selective cytotoxic effect and induces cell death on Hep G2 cells. J Agric Food Chem 2005; 53:1949-1954.
13. Akihisa T, Tokuda H, Ukiya M, Kiyota A, Yasukaw a K, Sakamoto N, et al. Antitumor-initiating effects of monascin, an azaphilonoid pigment from the extract of Monascus pilosus fermented rice (red-mold rice). Chem Biodivers 2005; 2:1305-1309. (Pubitemid 41645363)
14. Chen RJ, Hung CM, Chen YL,Wu MD, Yuan GF,Wang YJ. Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells via the Akt and AMPK signaling pathways. J Agric Food Chem 2012; 60:7185-7193.
15. Hsu LC, Hsu YW, Liang YH, Liaw CC, Kuo YH, Pan TM. Induction of apoptosis in human breast adenocarcinoma cells MCF-7 by monapurpyridine A, a new azaphilone derivative from Monascus pur pureus NTU 568. Molecules 2012; 17:664-673.
16. Hsu YW, Hsu LC, Liang YH, Kuo YH, Pan TM. Monaphilones A-C, three new antiproliferative azaphilone derivatives from Monascus purpureus NTU 568. J Agric Food Chem 2010; 58:8211-8216.
17. Ho BY, Pan TM. The Monascus metabolite monacolin K reduces tumor progression and metastasis of Lewis lung carcinoma cells. J Agric Food Chem 2009; 57:8258-8265.
18. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50:83-93. (Pubitemid 28438864)
19. Depasquale I,Wheatley DN, Action of lovastatin (Mevinolin) on an in vitro model of angiogenesis and its co-culture with malignant melanoma cell lines, Cancer Cell Int,2006,6,9-20.
20. Ajith TA, Soja M. A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens. Cell Biol Toxicol 2006; 22:269-274. (Pubitemid 44050816)
21. Lee BH, Hsu WH, Liao TH, Pan TM. Inhibition of leukemia proliferation by a novel polysaccharide identified from Monascus-fermented dioscorea via inducing differentiation. Food Funct 2012; 3:758-764.
22. Shang XY, Li JJ, Liu MT, Li S, Liu Y, Wang YF, et al. Cytotoxic steroids from Monascus purpureus-fermented rice. Steroids 2011; 76: 1185-1189.
23. Hong MY, Seeram NP, Zhang Y, Heber D. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 2008; 19:448-458. (Pubitemid 351783405)
24. Lee CI, Lee CL, Hwang JF, Lee YH,Wang JJ. Monascus-fermented red mold rice exhibits cytotoxic effect and induces apoptosis on human breast cancer cells. Appl Microbiol Biotechnol 2013; 97:1269-1278.
25. Ho BY, Wu YM, Hsu YW, Hsu LC, Kuo YH, Chang KJ, et al. Effects of Monascus-fermented rice extract on malignant cell-associated neovascularization and intravasation determined using the chicken embryo chorioallantoic membrane model. Integr Cancer Ther 2010; 9:204-212.
26. Hsu WH, Lee BH, Pan TM. Red mold dioscorea-induced G2/M arrest and apoptosis in human oral cancer cells. J Sci Food Agric 2010; 90: 2709-2715.
27. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51:3602-3609.
28. Yu X, Luo Y, Zhou Y, Zhang Q,Wang J,Wei N, et al. BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol 2008; 33:555-563.
29. Zhong WB, Hsu SP, Ho PY, Liang YC, Chang TC, Lee WS. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-reg ulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem Pharmacol 2011; 82:1663-1672.
30. Sane KM, Mynderse M, Lalonde DT, Dean IS,Wojtkowiak JW, Fouad F, et al. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J Pharmacol Exp Ther 2010; 333:23-33.
31. Shui HA, Hsia CW, Chen H M, Chang TC, Wang CY. Proteomics and bioinformatics analysis of lovastatin-induced differentiation in ARO cells. J Proteomics 2012; 75:1170-1180.
32. Lin WY, Hsu WY, Hish CH, Pan TM. Proteome changes in Caco-2 cells treated with Monascus-fermented red mold rice extract. J Agric Food Chem 2007; 55:8987-8994.
33. Hsu LC, Hsu YW, Liang YH, Kuo YH, Pan TM. Anti-tumor and anti inflammatory properties of ankaflavin and monaphilone A from Monascus purpureus NTU 568. J Agric Food Chem 2011; 59:1124-1130.
34. Maksimova E, Yie TA, Rom WN. In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung 2008; 186: 45-54.
35. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, et al. Breast cancer growth prevention by statins. Cancer Res 2006; 66:8707-8714. (Pubitemid 44449187)
36. Yang L, Egger M, Plattner R, Klocker H, Eder IE. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP pr ostate cancer cells. Urology 2011; 77:e1-e7.
37. Guruswamy S, Rao CV. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: implications for colon cancer prevention. Int J Oncol 2009; 35:1037-1043.
38. Kim W, Yoon JH, Kim JR, Jang IJ, Bang YJ, Kim YJ, et al. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibit or in hepatocellular carcinoma. Cancer Chemother Pharmacol 2009; 64:497-507.
39. Niknejad N, Gorn-Hondermann I, Ma L, Zahr S, Johnson-Obeseki S, Corsten M, et al. Lovastatin-induced ap optosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal. Int J Cancer 2014; 134:268-279.
40. Laezza C,Fiorentino L,Pisanti S,Gazzerro P,Caraglia M,Portella G,et al,Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state, J Mol Med (Berl),2008, 86,1341-1351.
41. Shi Y, Felley-Bosco E, Marti TM, Stahel RA. Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy. PLoS One 2012; 7:e45354.
42. WongWW, Clendening JW, Martirosyan A, Boutros PC, Bros C, Khosravi F, et al. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 2007; 6:1886-1897 . (Pubitemid 46954066)
43. Marcuzzi A, Zanin V, Piscianz E, Tricarico PM, Vuch J, Girardelli M, et al. Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line. Int J Dev Neurosci 201 2; 30:451-456.
44. Ma L, Niknejad N, Gorn-Hondermann I, Dayekh K, Dimitroulakos J. Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squa mous cell carcinoma cells. PLoS One 2012; 7:e46055.
45. Niknejad N, Morley M, Dimitroulakos J. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem 2007; 282:29748-29756. (Pubitemid 350035248)
46. Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, et al. NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One 2011; 6:e18306.
47. Asakura K, Izumi Y, Yamamoto M, Yamauchi Y, Kawai K, Serizawa A, et al. The cytostatic effects of lovastatin on ACC-MESO-1 cells. J Surg Res 2011; 170:e197-e209.
48. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, et al. Increased sensitivity of acute mye loid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999; 93:1308-1318. (Pubitemid 29076146)
49. De Jonge-Peeters SD, van der Weide K, Kuipers F, Sluiter WJ, de Vries EG, Velleng a E. Variability in responsiveness to lovastatin of the primitive CD34 + AML subfraction compared to normal CD34 + cells. Ann Hematol 2009; 88:573-580.
50. Kang S, Kim ES, Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep 2009; 21:1317-1322.
51. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. 3-Hydroxy-3-methylglu taryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122:308-317. (Pubitemid 34116983)
52. Lee J, Lee I, Park C, Kang WK. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun 2006; 339:748-754. (Pubitemid 41772877)
53. Zhong WB, Liang YC, Wang CY, Chang TC, Lee WS. Lovastatin suppresses invasiven ess of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 2005; 12:615-629.
54. Horiuchi A, Kikuchi N, Osada R, Wang C, Hayashi A, Nikaido T, et al. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci 2008; 99:2532-2539.
55. Dmoszynska A, Podhor ecka M, Klimek P, Grzasko N. Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. Eur J Clin Pharmacol 2006; 62: 325-329.
56. Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010; 28:791-799.
57. Sanli T, Liu C, Rashid A, Hopmans SN, Tsiani E, Schultz C, et al. Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 2011; 6:439-450.
58. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neuro oncol 2008; 90:9-17.
59. Zhao TT, Trinh D, Addison CL, Dimitroulakos J. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS One 2 010; 5:e12563.
60. Rozados VR, Hinrichsen LI, McDonnell J, Scharovsky OG. Lovastatin enhances in vitro radiation-induced apoptosis of rat B-cell lymphoma cells. J Exp Clin Cancer Res 2005; 24 :55-61. (Pubitemid 40655863)
61. Chiu HW, Fang WH, Chen YL, Wu MD, Yuan GF, Ho SY, et al. Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy. PLoS One 2012; 7:e40462.
62. Hong MY,Henning S,Moro A,Seeram NP,Zhang Y,Heber D, Chinese red yeast rice inhibition of prostate tumor growth in SCID mice, Can cer Prev Res (Phila), 2011,4,608-615.
63. Chiu HW, Chen MH, Fang WH, Hung CM, Chen YL, Wu MD, et al. Preventive effects of Monascus on androgen-related diseases: androgenetic alopecia, ben ign prostatic hyperplasia, and prostate cancer. J Agric Food Chem 2013; 61:4379-4386.
64. Tsai RL, Ho BY, Pan TM. Red mold rice mitigates oral carcinogenesis in 7,12-dimethyl-1,2-benzaanthracene-indu ced oral carcinogenesis in hamster. Evid Based Complement Alternat Med 2011; 2011: 245209.
65. Hsu WH, Lee BH, Pan TM. Effects of red mold dioscorea on oral carcinogenesis in DMBA-induced hamster animal model. Food Chem Toxicol 2011; 49:1292-1297.
66. Hsu WH, Lee BH, Pan TM. Protection of Monascus-fermented dioscorea against DMBA-induced oral injury in hamster by anti-inflammatory and antioxidat ive potentials. J Agric Food Chem 2010; 58:6715-6720.
67. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malign ancies. Cancer Chemother Pharmacol 2006; 57:155-164. (Pubitemid 41779834)
68. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, et al. A phase I trial of prolonged administration of lovasta tin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005; 41:523-1530.
69. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, et al. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat 2013; 142:389-398.
70. Martinkova L, Patakova-Juzlova P, Krent V, Kucerova Z, Havlicek V, Olsovsky P, et al. Biological activities of oligoketide pigments of Monascus purpureus. Food Addit Contam 1999; 16:15-24 . (Pubitemid 29043226)
71. Knecht A, Humpf HU. Cytotoxic and antimitotic effects of N-containing Monascus metabolites studied using immortalized human kidney epithelial cells. Mol Nutr Food Res 2006; 50:406-412.
72. Blanc PJ, Laussac JP, Le Bars J, Le Bars P, Loret MO, Pareilleux A, et al. Characterization of monascidin A from Monascus as citrinin. Int J Food Microbiol 1995; 27:201-213.
73. Chen F, Hu X. Study on red fermented rice with high concentration of monacolin K and low concentration of citrinin. Int J Food Microbiol 2005; 103:331-337. (Pubitemid 41138815)
74. Lee CL, Hung HK,Wang JJ, Pan TM. Improving the ratio of monacolin K to citrinin production of Monascus purpureus NTU 568 under dioscorea medium through the mediation of pH value and ethanol addition. J Agric Food Chem 2007; 55:6493-6502.
75. Hajjaj H, Francois JM, Goma G, Blanc PJ. Effect of amino acids on red pigments and citrinin production in Monascus ruber. J Food Sci 2012; 77:M156-M159.
76. Jia XQ, Xu ZN, Zhou LP, Sung CK. Elimination of the mycotoxin citrinin production in the industrial important strain Monascus purpureus SM001. Metab Eng 2010; 12:1-7.
77. Wang JJ, Lee CL, Pan TM. Modified mutation method for screening low citrinin-producing strains of Monascus purpureus on rice culture. J Agric Food Chem 2004; 52:6977-6982.
78. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010; 170:1722 -1727.